Neural Net Modeling of Checkpoint Inhibitor Related Myocarditis and Steroid Response

References

• Mahmood SS, Fradley MG, Cohen JV, et al. Myocarditis in patients treated with immune checkpoint inhibitors. J Am Coll Cardiol. 2018;71(16):1755–1764. doi:10.1016/j.jacc.2018.02.037
   PubMed Web of Science ®Google Scholar
• Takai M, Kato D, Iinuma K, et al. Simultaneous pembrolizumab-induced myasthenia gravis and myocarditis in a patient with metastatic bladder cancer: a case report. Urol Case Rep. 2020;31:101145. doi:10.1016/j.eucr.2020.101145
   PubMed Web of Science ®Google Scholar
• Nierstedt RT, Yeahia R, Barnett KM. Unanticipated myocarditis in a surgical patient treated with pembrolizumab: a case report. A A Pract. 2020;14(6):e01177. doi:10.1213/XAA.0000000000001177
   PubMed Web of Science ®Google Scholar
• Lee DH, Armanious M, Huang J, Jeong D, Druta M, Fradley MG. Case of pembrolizumab-induced myocarditis presenting as torsades de pointes with safe re-challenge. J Oncol Pharm Pract. 2020;1078155220904152. doi:10.1177/1078155220904152
   Web of Science ®Google Scholar
• Wang Q, Hu B. Successful therapy for autoimmune myocarditis with pembrolizumab treatment for nasopharyngeal carcinoma. Ann Transl Med. 2019;7(11):247. doi:10.21037/atm.2019.04.73
   PubMed Web of Science ®Google Scholar
• Hellman JB, Traynis I, Lin LK. Pembrolizumab and epacadostat induced fatal myocarditis and myositis presenting as a case of ptosis and ophthalmoplegia. Orbit. 2019;38(3):244–247. doi:10.1080/01676830.2018.1490439
   PubMed Web of Science ®Google Scholar
• Katsume Y, Isawa T, Toi Y, et al. Complete atrioventricular block associated with pembrolizumab-induced acute myocarditis: the need for close cardiac monitoring. Internal Med. 2018;57(21):3157–3162. doi:10.2169/internalmedicine.0255-17
   PubMed Web of Science ®Google Scholar
• Martinez-Calle N, Rodriguez-Otero P, Villar S, et al. Anti-PD1 associated fulminant myocarditis after a single pembrolizumab dose: the role of occult pre-existing autoimmunity. Haematologica. 2018;103(7):e318–e21. doi:10.3324/haematol.2017.185777
   PubMed Web of Science ®Google Scholar
• Inayat F, Masab M, Gupta S, Ullah W. New drugs and new toxicities: pembrolizumab-induced myocarditis. BMJ Case Rep. 2018;2018. doi:10.1136/bcr-2017-223252
   Google Scholar
• Nasr F, El Rassy E, Maalouf G, et al. Severe ophthalmoplegia and myocarditis following the administration of pembrolizumab. Eur J Cancer. 2018;91:171–173. doi:10.1016/j.ejca.2017.11.026
   PubMed Web of Science ®Google Scholar
• Laubli H, Balmelli C, Bossard M, Pfister O, Glatz K, Zippelius A. Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma. J Immunother Cancer. 2015;3(1):11. doi:10.1186/s40425-015-0057-1
   PubMed Web of Science ®Google Scholar
• Lie G, Weickhardt A, Kearney L, et al. Nivolumab resulting in persistently elevated troponin levels despite clinical remission of myocarditis and myositis in a patient with malignant pleural mesothelioma: case report. Transl Lung Cancer Res. 2020;9(2):360–365. doi:10.21037/tlcr.2020.02.05
   PubMed Web of Science ®Google Scholar
• Edahiro R, Shiroyama T, Hijiki S, et al. Severe myocarditis with slight lymphocytic infiltration after nivolumab treatment. Lung Cancer. 2020;140:116–117. doi:10.1016/j.lungcan.2019.12.004
   PubMed Web of Science ®Google Scholar
• Valenti-Azcarate R, Esparragosa Vazquez I, Toledano Illan C, Idoate Gastearena MA, Gallego Perez-Larraya J. Nivolumab and Ipilimumab-induced myositis and myocarditis mimicking a myasthenia gravis presentation. Neuromuscul Disord. 2020;30(1):67–69. doi:10.1016/j.nmd.2019.10.006
   PubMed Web of Science ®Google Scholar
• Tan JL, Mugwagwa AN, Cieslik L, Joshi R. Nivolumab-induced myocarditis complicated by complete atrioventricular block in a patient with metastatic non-small cell lung cancer. BMJ Case Rep. 2019;12(7):e229963. doi:10.1136/bcr-2019-229963
   PubMedGoogle Scholar
• Saibil SD, Bonilla L, Majeed H, et al. Fatal myocarditis and rhabdomyositis in a patient with stage IV melanoma treated with combined ipilimumab and nivolumab. Curr Oncol. 2019;26(3):e418–e21. doi:10.3747/co.26.4381
   PubMed Web of Science ®Google Scholar
• Martin Huertas R, Saavedra Serrano C, Perna C, Ferrer Gomez A, Alonso Gordoa T. Cardiac toxicity of immune-checkpoint inhibitors: a clinical case of nivolumab-induced myocarditis and review of the evidence and new challenges. Cancer Manag Res. 2019;11:4541–4548. doi:10.2147/CMAR.S185202
   PubMed Web of Science ®Google Scholar
• Fazel M, Jedlowski PM. Severe myositis, myocarditis, and myasthenia gravis with elevated anti-striated muscle antibody following single dose of ipilimumab-nivolumab therapy in a patient with metastatic melanoma. Case Reports in Immunology. 2019;2019:2539493. doi:10.1155/2019/2539493
   PubMed Web of Science ®Google Scholar
• Matsuo K, Ishiguro T, Najama T, Shimizu Y, Kobayashi Y, Mutou M. Nivolumab-induced myocarditis successfully treated with corticosteroid therapy: a case report and review of the literature. Internal Med. 2019;58(16):2367–2372. doi:10.2169/internalmedicine.2596-18
   PubMed Web of Science ®Google Scholar
• Monge C, Maeng H, Brofferio A, et al. Myocarditis in a patient treated with Nivolumab and PROSTVAC: a case report. J Immunother Cancer. 2018;6(1):150. doi:10.1186/s40425-018-0473-0
   PubMed Web of Science ®Google Scholar
• Yamaguchi S, Morimoto R, Okumura T, et al. Late-onset fulminant myocarditis with immune checkpoint inhibitor nivolumab. Can J Cardiol. 2018;34(6):812e1- e3. doi:10.1016/j.cjca.2018.03.007
   Web of Science ®Google Scholar
• Chen Q, Huang DS, Zhang LW, Li YQ, Wang HW, Liu HB. Fatal myocarditis and rhabdomyolysis induced by nivolumab during the treatment of type B3 thymoma. Clin Toxicol. 2018;56(7):667–671. doi:10.1080/15563650.2017.1401079
   PubMed Web of Science ®Google Scholar
• Fukasawa Y, Sasaki K, Natsume M, et al. Nivolumab-induced myocarditis concomitant with myasthenia gravis. Case Rep Oncol. 2017;10(3):809–812. doi:10.1159/000479958
   PubMed Web of Science ®Google Scholar
• Matson DR, Accola MA, Rehrauer WM, Corliss RF. Fatal myocarditis following treatment with the PD-1 inhibitor nivolumab. J Forensic Sci. 2018;63(3):954–957. doi:10.1111/1556-4029.13633
   PubMed Web of Science ®Google Scholar
• Suzuki S, Ishikawa N, Konoeda F, et al. Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan. Neurology. 2017;89(11):1127–1134. doi:10.1212/WNL.0000000000004359
   PubMed Web of Science ®Google Scholar
• Sauer R, Kiewe P, Desole M, et al. Lymphozytäre Myokarditis unter Nivolumabtherapie bei metastasiertem klarzelligen Nierenzellkarzinom. Pathologe. 2017;38(6):535–539. German. doi:10.1007/s00292-017-0349-y
   PubMed Web of Science ®Google Scholar
• Tay RY, Blackley E, McLean C, et al. Successful use of equine anti-thymocyte globulin (ATGAM) for fulminant myocarditis secondary to nivolumab therapy. Br J Cancer. 2017;117(7):921–924. doi:10.1038/bjc.2017.253
   PubMed Web of Science ®Google Scholar
• Tadokoro T, Keshino E, Makiyama A, et al. Acute lymphocytic myocarditis with anti-PD-1 antibody nivolumab. Circ Heart Fail. 2016;9(10). doi:10.1161/CIRCHEARTFAILURE.116.003514
   PubMed Web of Science ®Google Scholar
• Semper H, Muehlberg F, Schulz-Menger J, Allewelt M, Grohe C. Drug-induced myocarditis after nivolumab treatment in a patient with PDL1- negative squamous cell carcinoma of the lung. Lung Cancer. 2016;99:117–119. doi:10.1016/j.lungcan.2016.06.025
   PubMed Web of Science ®Google Scholar
• Gibson R, Delaune J, Szady A, Markham M. Suspected autoimmune myocarditis and cardiac conduction abnormalities with nivolumab therapy for non-small cell lung cancer. BMJ Case Rep. 2016;2016. doi:10.1136/bcr-2016-216228
   PubMedGoogle Scholar
• Mehta A, Gupta A, Hannallah F, Koshy T, Reimold S. Myocarditis as an immune-related adverse event with ipilimumab/nivolumab combination therapy for metastatic melanoma. Melanoma Res. 2016;26(3):319–320. doi:10.1097/CMR.0000000000000251
   PubMed Web of Science ®Google Scholar
• Samara Y, Yu CL, Dasanu CA. Acute autoimmune myocarditis and hepatitis due to ipilimumab monotherapy for malignant melanoma. J Oncol Pharm Pract. 2019;25(4):966–968. doi:10.1177/1078155218755868
   PubMed Web of Science ®Google Scholar
• Reuben A, Petaccia de Macedo M, McQuade J, et al. Comparative immunologic characterization of autoimmune giant cell myocarditis with ipilimumab. Oncoimmunology. 2017;6(12):e1361097. doi:10.1080/2162402X.2017.1361097
   PubMed Web of Science ®Google Scholar
• Berg DD, Vaduganathan M, Nohria A, et al. Immune-related fulminant myocarditis in a patient receiving ipilimumab therapy for relapsed chronic myelomonocytic leukaemia. Eur J Heart Fail. 2017;19(5):682–685. doi:10.1002/ejhf.806
   PubMed Web of Science ®Google Scholar
• Gupta R, Zaid S, Sayed A, et al. Atezolizumab induced myocarditis on a background of cardiac amyloidosis. Am J Ther. 2019;26(6):e795–e7. doi:10.1097/MJT.0000000000000968
   PubMed Web of Science ®Google Scholar
• Mahmood SS, Chen CL, Shapnik N, Krishnan U, Singh HS, Makker V. Myocarditis with tremelimumab plus durvalumab combination therapy for endometrial cancer: a case report. Gynecol Oncol Rep. 2018;25:74–77. doi:10.1016/j.gore.2018.05.014
   PubMed Web of Science ®Google Scholar
• Touat M, Maisonobe T, Knauss S, et al. Immune checkpoint inhibitor-related myositis and myocarditis in patients with cancer. Neurology. 2018;91(10):e985–e94. doi:10.1212/WNL.0000000000006124
   PubMed Web of Science ®Google Scholar
• Puzanov I, Diab A, Abdallah K, et al.; Society for Immunotherapy of Cancer Toxicity Management Working Group. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. J Immunother Cancer. 2017;5(1):95. doi:10.1186/s40425-017-0300-z
   PubMed Web of Science ®Google Scholar
• Neilan TG, Rothenberg ML, Amiri-Kordestani L, et al.; Checkpoint Inhibitor Safety Working Group. Myocarditis associated with immune checkpoint inhibitors: an expert consensus on data gaps and a call to action. Oncologist. 2018;23(8):874–878. doi:10.1634/theoncologist.2018-0157
   PubMed Web of Science ®Google Scholar
• Johnson DB, Balko JM, Compton ML, et al. Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med. 2016;375(18):1749–1755. doi:10.1056/NEJMoa1609214
   PubMed Web of Science ®Google Scholar
• Patrinely JR, McGuigan B, Chandra S, et al. A multicenter characterization of hepatitis associated with immune checkpoint inhibitors. Oncoimmunology. 2021;10(1):1875639. doi:10.1080/2162402X.2021.1875639
   PubMed Web of Science ®Google Scholar
• Guidon AC, Burton LB, Chwalisz BK, et al. Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors. J Immunother Cancer. 2021;9(7):e002890. doi:10.1136/jitc-2021-002890
   PubMed Web of Science ®Google Scholar
• Wang DY, Mooradian MJ, Kim D, et al. Clinical characterization of colitis arising from anti-PD-1 based therapy. Oncoimmunology. 2019;8(1):e1524695. doi:10.1080/2162402X.2018.1524695
   PubMed Web of Science ®Google Scholar
• Johnson DB, Taylor KB, Cohen JV, et al. Anti-PD-1-induced pneumonitis is associated with persistent imaging abnormalities in melanoma patients. Cancer Immunol Res. 2019;7(11):1755–1759. doi:10.1158/2326-6066.CIR-18-0717
   PubMed Web of Science ®Google Scholar
• Xu D, Zhao RC, Gao WH, Cui HB. A risk prediction model for in-hospital mortality in patients with suspected myocarditis. Chin Med J. 2017;130(7):782–790. doi:10.4103/0366-6999.202747
   PubMed Web of Science ®Google Scholar
• Jacobs DM, Stefanovic F, Wilton G, Gomez-Caminero A, Schentag JJ. An integrated epidemiological and neural net model of the warfarin effect in managed care patients. Clin Pharmacol. 2017;9:55–64. doi:10.2147/CPAA.S136243
   PubMed Web of Science ®Google Scholar
• Puzanov I, Subramanian P, Yatsynovich YV, et al. Clinical characteristics, time course, treatment and outcomes of patients with immune checkpoint inhibitor-associated myocarditis. J Immunother Cancer. 2021;9(6):e002553. doi:10.1136/jitc-2021-002553
   PubMed Web of Science ®Google Scholar
• Hwang M, Leem CH, Shim EB. Toward a grey box approach for cardiovascular physiome. Korean J Physiol Pharmacol. 2019;23(5):305–310. doi:10.4196/kjpp.2019.23.5.305
   PubMed Web of Science ®Google Scholar